@article{ATM25238,
author = {Guochun Zhang and Yulei Wang and Bo Chen and Liping Guo and Li Cao and Chongyang Ren and Lingzhu Wen and Kai Li and Minghan Jia and Cheukfai Li and Hsiaopei Mok and Xiaoqing Chen and Guangnan Wei and Jiali Lin and Zhou Zhang and Ting Hou and Han Han-Zhang and Chenglin Liu and Hao Liu and Jing Liu and Charles M. Balch and Funda Meric-Bernstam and Ning Liao},
title = {Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts},
journal = {Annals of Translational Medicine},
volume = {7},
number = {8},
year = {2019},
keywords = {},
abstract = {Background: The complexity of breast cancer at the clinical, morphological and genomic levels has been extensively studied in the western population. However, the mutational genomic profiles in Chinese breast cancer patients have not been explored in any detail.
Methods: We performed targeted sequencing using a panel consisting of 33 breast cancer-related genes to investigate the genomic landscape of 304 consecutive treatment-naïve Chinese breast cancer patients at Guangdong Provincial People’s Hospital (GDPH), and further compared the results to those in 453 of Caucasian breast cancer patients from The Cancer Genome Atlas (TCGA).
Results: The most frequently mutated gene was TP53 (45%), followed by PIK3CA (44%), GATA3 (18%), MAP3K1 (10%), whereas the copy-number amplifications were frequently observed in genes of ERBB2 (24%), MYC (23%), FGFR1 (13%) and CCND1 (10%). Among the 8 most frequently mutated or amplified genes, at least one driver was identifiable in 87.5% (n=267) of our GDPH cohort, revealing the significant contribution of these known driver genes in the development of Chinese breast cancer. Compared to TCGA data, the median age at diagnosis in our cohort was significantly younger (48 vs. 58 years; P},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/25238}
}